Anchored in work undertaken by one of the principals at University Buffalo andhaving limited SBIR involvement, Empire Genomics is a molecular and cytogenetic diagnostics company offering a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. With services designed specifically to meet the needs of pathologists, oncologists, and researchers, the firm is organized around enableing personalized medicine through the development and implementation of genetic assays. As this form of testing becomes more accessible and affordable,the objective is to enable faster and more effective drug development, lower healthcare costs, and better clinical outcomes. The firm uses utilizes a proprietary technique that allows for the detection of chromosomal aberrations. The firm is a molecular and cytogenetic diagnostics company offering a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. Designed to specifically meet the needs of pathologists, oncologists, and researchers, the effort is to enable personalized medicine through the development and implementation of genetic assays. Making this testing more accessible and affordable will support faster and more effective drug development, lower healthcare costs, and better clinical outcomes. The firm's genomic platform supports research and diagnostic applications in cancer biology, biomarkers, drug discovery, prenatal screening, developmental disorders, autism and many more genomic related areas. Empire Genomics manufactures human BAC arrayed slides for array comparative genomic hybridization, as well as for discovery of genomic aberrations related to disease states, including cancer, autism, schizophrenia, mental retardation, and several congenital abnormalities; microarray-based comparative genomic hybridization technology; bacterial artificial chromosome clones for functional genomics research; probes to detect or confirm genetic abnormalities in the human genome; gene expression analysis that allows customers to send in RNA or sample material using the Agilent oligonucleotide array platform; and BioDiscovery's ImaGene CGH analytics software package. In November 2022 it was announced that San Francisco-based company Biocare Medical - a provider of immunohistochemistry instrumentation - had acquired Empire Genomics with indication that the acquired firm will function as a subsiduary of Biocare Medical.
